Ch55 - CAS# 110368-33-7 )-Polydatin Tavaborole began its Phase 3

Tavaborole began its Phase 3 trials in December 2010 and was approved in July 2014

Smiles: CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@]53CC[C@@]21C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1OC(C)=O)C4(C)C

and significantly decreased IL-17 and ameliorated the pathological symptoms

24 hours) shows obvious effect on disturbing the interaction of transmembrane protein CD14 with Toll-like receptor-4

Ch55 - CAS# 110368-33-7 )-Polydatin Tavaborole began its Phase 3Ch55 is a potent synthetic retinoid. Ch55 binds to RAR and RAR receptors with high affinity. Ch55 displays low affinity for cellular retinoic acid binding protein (CRABP). Ch55 is a potent inducer of the differentiation of HL60 cells with an EC50 of 200 nM. Ch55 can be used for cancer research. Product information CAS Number: 110368 33 7 Molecular Weight: 364. 48 Formula: C24H28O3 Chemical Name: 4 [(1E) 3 (3,5 di tert butylphenyl) 3 oxoprop 1 en 1